Menu

Boehringer Ingelheim

Crystal Bioscience and Boehringer Ingelheim Announce Multiple Target Antibody Discovery Collaboration

, , ,

EMERYVILLE, CA and INGELHEIM, Germany, 7 January – Crystal Bioscience Inc. (Crystal) and Boehringer Ingelheim announced today that they have entered into an agreement to collaborate on the discovery and development of therapeutic antibodies. Crystal Bioscience will apply its proprietary gel encapsulated microenvironment (GEM) and chicken immunization platforms to discover antibodies to multiple targets selected by […]

Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product

, , , , ,

New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 20, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an […]

Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders

, , , ,

Menlo Park, California and INGELHEIM, Germany, 18 December, 2013 – Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors. […]

Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation

, , , , ,

More than 10,000 people with self-reported and diagnosed type 2 diabetes and more than 6,500 treating-physicians from 26 countries to take part in new survey RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 2, 2013 /PRNewswire/ — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the launch of the largest multinational survey to investigate early […]

Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests

, , , ,

TUCSON, Arizona and INGELHEIM, Germany, 19 September 2013 – Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, and Boehringer Ingelheim (BI) announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim Oncology programmes. As part of the agreement, Ventana will utilize its […]